Want to see IN:ERIS full AI Analyst Report?
ERIS Stock Chart & Stats
₹1398.90
₹2.90(0.21%)
At close: 4:00 PM EDT
₹1398.90
₹2.90(0.21%)
Day’s Range― - ―
52-Week Range₹1,237.90 - ₹1,854.00
Previous CloseN/A
Volume38.23K
Average Volume (3M)2.07K
Market Cap
₹187.46B
Enterprise Value₹202.70K
Total Cash (Recent Filing)₹673.00M
Total Debt (Recent Filing)₹23.59B
Price to Earnings (P/E)28.8
Beta0.59
Next Earnings
Oct 23, 2026EPS Estimate
11.3Next Dividend Ex-DateN/A
Dividend Yield0.53%
Share Statistics
EPS (TTM)45.40
Shares Outstanding138,578,490
10 Day Avg. Volume1,915
30 Day Avg. Volume2,071
Financial Highlights & Ratios
PEG Ratio0.38
Price to Book (P/B)4.54
Price to Sales (P/S)5.67
P/FCF Ratio354.08
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)49.54
Revenue Forecast (FY)₹35.42B
Bulls Say, Bears Say
Bulls Say
Operating ProfitabilitySustained high gross and EBIT margins indicate durable pricing power and efficient cost structure in branded formulations. Consistently strong margins provide internal funding for marketing and product development, supporting long-term cash generation and competitive reinvestment capacity.
Improving LeverageMaterial reduction in leverage over recent years improves financial flexibility and reduces interest burden, enabling the company to better fund growth initiatives or absorb shocks. This trend lowers refinancing risk and strengthens the balance sheet over the medium term.
Chronic Branded PortfolioA portfolio concentrated in chronic and lifestyle therapies creates recurring demand and stronger physician prescribing patterns, supporting stable revenue streams. This structural market positioning helps sustain revenue visibility and brand equity across economic cycles.
Bears Say
Weak Cash GenerationA sharp drop in operating cash flow and FCF compression materially weakens cash conversion, constraining capital allocation flexibility. Persistent low FCF relative to earnings limits ability to invest, pay down debt, or return cash to shareholders without relying on external funding.
Earnings Quality VolatilitySignificant swings in margins and abnormal prior-year peaks reduce predictability of sustainable earnings. This variability suggests product-mix, pricing, or one-off effects that complicate forecasting and weaken confidence in the durability of reported profitability over the medium term.
Elevated Structural DebtAlthough leverage has improved, absolute debt remains significant and is meaningfully above historical lows, increasing financial risk. Elevated structural debt raises interest and refinancing exposure, which can limit strategic flexibility if cash generation does not stabilize.
Eris Lifesciences Ltd News
ERIS FAQ
What was Eris Lifesciences Ltd’s price range in the past 12 months?
Eris Lifesciences Ltd lowest stock price was ₹1237.90 and its highest was ₹1854.00 in the past 12 months.
What is Eris Lifesciences Ltd’s market cap?
Eris Lifesciences Ltd’s market cap is ₹187.46B.
When is Eris Lifesciences Ltd’s upcoming earnings report date?
Eris Lifesciences Ltd’s upcoming earnings report date is Oct 23, 2026 which is in 81 days.
How were Eris Lifesciences Ltd’s earnings last quarter?
Eris Lifesciences Ltd released its earnings results on Jul 29, 2026. The company reported ₹10.3 earnings per share for the quarter, missing the consensus estimate of ₹10.767 by -₹0.467.
Is Eris Lifesciences Ltd overvalued?
According to Wall Street analysts Eris Lifesciences Ltd’s price is currently Overvalued.
Does Eris Lifesciences Ltd pay dividends?
Eris Lifesciences Ltd pays a Notavailable dividend of ₹7.21 which represents an annual dividend yield of 0.53%. See more information on Eris Lifesciences Ltd dividends here
What is Eris Lifesciences Ltd’s EPS estimate?
Eris Lifesciences Ltd’s EPS estimate is 11.3.
How many shares outstanding does Eris Lifesciences Ltd have?
Eris Lifesciences Ltd has 138,578,490 shares outstanding.
What happened to Eris Lifesciences Ltd’s price movement after its last earnings report?
Eris Lifesciences Ltd reported an EPS of ₹10.3 in its last earnings report, missing expectations of ₹10.767. Following the earnings report the stock price went up 2.573%.
Which hedge fund is a major shareholder of Eris Lifesciences Ltd?
Currently, no hedge funds are holding shares in IN:ERIS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Eris Lifesciences Ltd
Eris Lifesciences Limited is an Indian pharmaceutical company engaged in the manufacturing, marketing, and distribution of medicinal products throughout the country. The company provides a comprehensive range of branded formulations, catering to a wide spectrum of therapeutic areas. These encompass cardiovascular health, anti-diabetic treatments, anti-infectives, antipyretics, vitamin/nutrient supplements, gastroenterology, respiratory care, gynecology, pediatrics, neurology, psychiatry, and pain/analgesics, alongside services in in-vitro fertilization, cosmetology, and dermatology. Founded in 2007, Eris Lifesciences Limited is headquartered in Ahmedabad, India.
Technical Analysis
Alkem Laboratories Ltd.
―
Alembic Pharmaceuticals Limited
―
Glenmark Pharmaceuticals Limited
―
Mankind Pharma Ltd.
―
Torrent Pharmaceuticals Ltd
―